Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis drug Votubia® recommended by CHMP for approval in the EU 24 June 2011
Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 17 June 2011
Novartis gains European Commission approval for Lucentis® 07 June 2011
Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly 25 May 2011
Novartis receives EU approval for Rasilamlo® 28 April 2011
Novartis makes strong start for the year 20 April 2011
Novartis receives European Commission approval for Gilenya® 21 March 2011
Novartis gains positive CHMP opinion for Rasilamlo(TM) 21 February 2011
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET 09 February 2011
Innovation drives Novartis to double-digit growth for 2010 30 January 2011
Sandoz announces phase II clinical trial for biosimilar version of rituximab 13 January 2011
Novartis submits Bexsero® for regulatory review in Europe 02 January 2011
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases 02 December 2010
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 18 November 2010
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate 04 November 2010
Novartis therapy Lucentis® recommended for approval in EU 25 October 2010
Novartis delivers excellent performance in third quarter 22 October 2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy 13 October 2010
Novartis announces agreement to develop influenza vaccines 08 October 2010
Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® 28 September 2010